The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics

Laura C Coates, William Tillett, David Chandler, Philip S Helliwell, Eleanor Korendowych, Stuart Kyle, Iain B McInnes, Susan Oliver, Anthony Ormerod, Catherine Smith, Deborah Symmons, Nicola Waldron, Neil J McHugh, BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR

Research output: Contribution to journalArticle

60 Citations (Scopus)
Original languageEnglish
Pages (from-to)1754-1757
Number of pages4
JournalRheumatology
Volume52
Issue number10
Early online date25 Jul 2013
DOIs
Publication statusPublished - Oct 2013

Keywords

  • algorithms
  • antirheumatic agents
  • arthritis, psoriatic
  • biological products
  • humans
  • treatment failure
  • tumor necrosis factor-alpha
  • biologics
  • treatment
  • management
  • guidelines
  • recommendations
  • anti-TNF therapies
  • psoriasis
  • enthesitis
  • dactylitis

Cite this

Coates, L. C., Tillett, W., Chandler, D., Helliwell, P. S., Korendowych, E., Kyle, S., McInnes, I. B., Oliver, S., Ormerod, A., Smith, C., Symmons, D., Waldron, N., McHugh, N. J., & BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR (2013). The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology, 52(10), 1754-1757. https://doi.org/10.1093/rheumatology/ket187